William Blair Thinks Larimar Therapeutics’ Stock is Going to Recover

In a report issued on July 16, Myles Minter from William Blair initiated coverage with a Buy rating on Larimar Therapeutics (LRMRResearch Report). The company’s shares closed last Friday at $9.61, close to its 52-week low of $7.00.

According to TipRanks.com, Minter is a 4-star analyst with an average return of 17.9% and a 50.0% success rate. Minter covers the Healthcare sector, focusing on stocks such as Praxis Precision Medicines, Ionis Pharmaceuticals, and Minerva Neurosciences.

Larimar Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $30.00.

See today’s analyst top recommended stocks >>

Based on Larimar Therapeutics’ latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $12.09 million. In comparison, last year the company had a GAAP net loss of $6.67 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Zafgen, Inc. is a biopharmaceutical company, which engages in the development of novel therapies for patients affected by complex metabolic diseases. It focuses on the study of MetAP2 inhibitors in both common and rare metabolic disorders. The firm also advancing programs for type 2 diabetes, Prader-Willi syndrome, and liver diseases. The company was founded on November 22, 2005 and is headquartered in Boston, MA.